The Valley Desk

ArticleClinical breast cancerPublished

Detrimental Impact of Chemotherapy Dose Reduction or Discontinuation in Early Stage Triple-Negative Breast Cancer Treated With Pembrolizumab and Neoadjuvant Chemotherapy: A Multicenter Experience

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Article
Venue
Clinical breast cancer
Published
Subject terms
Humans; Antineoplastic Combined Chemotherapy Protocols; Neoplasm Staging; Chemotherapy, Adjuvant; Neoadjuvant Therapy; Retrospective Studies; Adult; Middle Aged; Female; Antibodies, Monoclonal, Humanized; Triple Negative Breast Neoplasms; Antineoplastic Agents, Immunological
PubMed ID
39198116
PubMed Central ID
PMC12838138
Added to directory
Source checked

Report a correction or request removal